Processa Pharmaceuticals Inc
PCSA - Insider Information
Get informed when a big investor buys or sells
+ FollowMarket Cap$5.29M
Close$
$4.23
128.6% upside
Current Fair Value
128.6% upsideUndervalued by 128.6% based on the discounted cash flow analysis.
Insider Trades
Loading insider trades…
Congress Trades
Loading congress trades…
Share Statistics
| Market cap | $5.29 Million |
|---|---|
| Enterprise Value | $5.09 Million |
| Earnings per Share | $-10.36 |
| Beta | 0.97 |
| Outstanding Shares | 2,750,742 |
Return
| Return on Equity | 4234.62% |
|---|---|
| Return on Assets | -649.33% |
| Return on Invested Capital | -3225.03% |
Valuation & Multiples
| P/E Ratio | -0.34 |
|---|---|
| PEG | 1.99 |
| Price to Sales | - |
| Price to Book Ratio | -1.85 |
| Enterprise Value to Revenue | - |
| Enterprise Value to EBIT | 0.5 |
| Enterprise Value to Net Income | -1 |
| Total Debt to Enterprise | 0 |
| Debt to Equity | 0 |
Revenue Sources
No data
Last Earnings Call
Report Date
October 30, 2026
EPS Estimate
$-1.00
Consensus analyst estimateRevenue Estimate
-
Consensus analyst estimateNext Earnings Call
Expected Date
November 2, 2026
EPS Estimate
$-1.00
Consensus analyst estimateRevenue Estimate
-
Consensus analyst estimateInstitutional Sentiment (Put/Call)
No data available for the latest quarter.
Institutional Ownership
No data available for the latest quarter.
About Processa Pharmaceuticals Inc
14 employees
Processa Pharmaceuticals, Inc. was founded in 2017 in Hanover, Maryland, with a mission to develop products that can improve the survival and/or quality of life for patients who have a high unmet medical need. The Company acquired the as...